From Bench to IND: The Regulatory Threshold for Peptide Therapeutics

Before any investigational peptide compound may be administered to human subjects in the United States, the sponsoring organization must submit an Investigational New Drug (IND) application to the Food and Drug Administration. The IND is not an approval to market a drug—it is a formal authorization to conduct clinical research, predicated on the FDA's determination that the proposed investigation does not expose participants to unreasonable risk [1].

For small molecules, the path to IND submission is well-trodden. Peptide therapeutics, however, occupy a more complex regulatory space. Their intermediate size—larger than conventional small molecules yet distinct from full biologics—creates analytical and manufacturing challenges that FDA reviewers have increasingly codified into specific expectations. Understanding those expectations is essential for any research institution or pharmaceutical sponsor planning a first-in-human study.

The Three-Module Architecture of an IND Application

Under 21 CFR 312.23, an IND application is organized into three core technical modules: Chemistry, Manufacturing, and Controls (CMC); Pharmacology and Toxicology; and Previous Human Experience [2]. A fourth section covers the clinical protocol and investigator information, but the scientific weight of the submission rests on the first two.

For peptide therapeutics, the CMC module typically requires more extensive documentation than an equivalent small-molecule submission. This is partly a function of structural complexity—peptides can adopt multiple conformational states, are susceptible to degradation pathways unavailable to small molecules, and are often manufactured through processes (solid-phase peptide synthesis or recombinant expression) that introduce a distinct class of process-related impurities. FDA reviewers assess whether the sponsor has characterized the compound sufficiently to ensure that what enters a human subject is what the sponsor believes it to be.

Chemistry, Manufacturing, and Controls: Core Requirements

Manufacturing Process and Batch Consistency

The CMC section must describe the manufacturing process in sufficient detail to allow FDA to assess process control and reproducibility. For synthetic peptides, this includes the synthesis route, resin and reagent specifications, coupling conditions, cleavage and deprotection steps, and purification methodology—typically reverse-phase high-performance liquid chromatography [3].

Batch-to-batch consistency is a central concern. FDA reviewers expect sponsors to provide data from at least representative batches demonstrating that the manufacturing process yields material of consistent identity, purity, and potency. Variability in aggregation state, for instance, can alter pharmacokinetic behavior and immunogenicity risk—two outcomes with direct implications for participant safety.

Impurity Characterization

Impurity profiling for peptides is considerably more demanding than for small molecules. Related substances—truncated sequences, deletion peptides, oxidized or deamidated variants, and racemized residues—must be identified and quantified [3]. The FDA's 2018 guidance on peptide drug products clarified that sponsors are expected to characterize impurities present above defined thresholds and to demonstrate that those impurities do not pose unacceptable safety risks [1].

For peptides produced through recombinant or cell-based manufacturing, process-related impurities extend to host cell proteins, residual DNA, and endotoxin. Endotoxin limits for injectable formulations are governed by established pharmacopeial standards, and the IND must include validated methods demonstrating that the drug substance and drug product meet those limits. Sterility testing protocols for parenteral peptide formulations are similarly required.

Analytical Methods and Reference Standards

The CMC section must include descriptions of all analytical methods used to characterize the drug substance and drug product, along with evidence of their suitability for the intended purpose. For peptides, this typically encompasses amino acid analysis or mass spectrometry for identity confirmation, HPLC for purity determination, and bioassays or receptor-binding assays for potency.

Higher-order structure characterization has become an increasingly expected component of peptide CMC packages. Circular dichroism, nuclear magnetic resonance spectroscopy, or dynamic light scattering data may be requested where the compound's activity is conformation-dependent. FDA reviewers have issued deficiency letters when sponsors submitted purity data without addressing whether the purified material retained the structural attributes associated with its pharmacological activity.

Reference standard qualification—establishing a well-characterized material against which all subsequent lots are measured—must be documented. The reference standard serves as the anchor for potency and purity comparisons across the development program.

Stability Protocols

Stability data must support the proposed shelf life of the drug substance and drug product through the duration of the clinical study. For early-phase INDs, real-time stability data may be limited, but sponsors are expected to provide an accelerated stability protocol and preliminary data demonstrating that the material is stable under proposed storage conditions. Peptides are particularly susceptible to hydrolysis, oxidation, and aggregation under stress conditions, and the stability program must address these degradation pathways explicitly.

The Nonclinical Safety Package

GLP Toxicology Studies

The pharmacology and toxicology module must include data sufficient to establish that human exposure at the proposed starting dose is reasonably safe. For most peptide INDs, this requires at least one Good Laboratory Practice (GLP)-compliant repeated-dose toxicology study in a relevant animal species [2]. Relevance is determined by whether the species expresses the target receptor or pathway in a manner comparable to humans—a criterion that can be difficult to satisfy for highly selective peptides with limited cross-species activity.

The choice of species, dose levels, route of administration, and duration of the toxicology study must be justified in the submission. FDA expects the toxicology studies to use a route of administration consistent with the proposed clinical route—an important consideration for peptides, which are frequently developed as subcutaneous or intravenous injectables.

Pharmacology and ADME Data

Primary pharmacology data—demonstrating that the compound engages its intended target and produces the expected biological effect in preclinical models—must be included. Secondary pharmacology data, addressing off-target activity, is also expected, particularly for peptides with structural similarity to endogenous signaling molecules that may interact with multiple receptor subtypes.

Absorption, distribution, metabolism, and excretion (ADME) data inform the selection of the starting dose and help predict human pharmacokinetics. Peptides are generally subject to proteolytic degradation rather than cytochrome P450-mediated metabolism, and this distinction should be addressed in the ADME section. Plasma stability data, tissue distribution studies, and excretion profiling are standard components of the nonclinical package.

Immunogenicity and Anti-Drug Antibody Assessment

Immunogenicity assessment has become a mandatory component of nonclinical packages for peptide therapeutics. FDA guidance on immunogenicity assessment for therapeutic protein and peptide products establishes that sponsors must evaluate the potential for anti-drug antibody (ADA) formation and characterize the likely consequences—including neutralization of pharmacological activity and potential hypersensitivity reactions [4].

For peptides, immunogenicity risk is influenced by sequence homology to endogenous proteins, the presence of non-natural amino acids or modifications, aggregation propensity, and the proposed dosing regimen. Nonclinical ADA assays are not always predictive of human immunogenicity, but their absence from an IND package is a recognized deficiency trigger. Sponsors are expected to describe the assay methodology, detection thresholds, and plans for ADA monitoring in the clinical study.

Aggregation Risk

Aggregation is a peptide-specific concern that bridges CMC and nonclinical safety. Aggregated peptide species can be immunogenic, alter pharmacokinetics, and in some cases produce toxic effects distinct from those of the monomeric compound. FDA reviewers expect sponsors to characterize the aggregation state of the drug substance under manufacturing and storage conditions, and to address whether aggregated species are present in the material used in toxicology studies [3].

Common IND Deficiency Patterns for Peptides

FDA's review clock for a standard IND is 30 days from receipt. If the agency identifies safety concerns or information deficiencies, it may place the IND on clinical hold—effectively pausing the program until the sponsor provides satisfactory responses. Understanding common deficiency patterns is therefore of practical importance.

Terminal Variant Characterization

N- and C-terminal variants—including truncated sequences, pyroglutamate formation at the N-terminus, and amidation or free-acid heterogeneity at the C-terminus—are among the most frequently cited CMC deficiencies for synthetic peptides. These variants may have different potency, stability, or immunogenicity profiles compared to the intended sequence, and their presence above threshold levels requires characterization and justification [3].

Insufficient Analytical Method Validation

Sponsors sometimes submit analytical data generated by methods that have not been adequately validated for specificity, linearity, and precision. FDA reviewers have cited this as a deficiency where the proposed method cannot reliably distinguish the active peptide from closely related impurities—a particular challenge when impurities differ by a single amino acid or a post-translational modification.

Starting Dose Justification

The proposed Phase 1 starting dose must be derived from nonclinical data using a documented methodology. For peptides, the minimum anticipated biological effect level (MABEL) approach is often appropriate, particularly where the compound has high potency or where the pharmacological target is expressed in humans at levels that may amplify effects observed in animal models. Submissions that rely solely on a fraction of the no-observed-adverse-effect level (NOAEL) without considering pharmacodynamic endpoints have drawn deficiency letters where the pharmacological effect is the primary safety concern.

Post-Translational Modification Control

For recombinantly expressed peptides, post-translational modifications—glycosylation, phosphorylation, disulfide bond formation—must be characterized and controlled. Variability in modification patterns between batches can affect potency and immunogenicity. FDA expects sponsors to demonstrate that their manufacturing process consistently produces material with a defined modification profile and to include this characterization in the CMC section.

Regulatory Precedent: The 2018 Peptide Guidance and Its Implications

FDA's 2018 guidance document on the classification of products as drugs and biological products, along with related guidance addressing peptide drug products, clarified the regulatory pathway for peptides of 40 amino acids or fewer that are chemically synthesized [1]. This guidance established that such peptides are generally regulated as drugs under the Federal Food, Drug, and Cosmetic Act rather than as biologics under the Public Health Service Act—a distinction with implications for the applicable CMC standards and the pathway to approval.

The guidance also reinforced expectations for purity, potency, and identity testing that align with those applied to small-molecule drugs while acknowledging the additional complexity of peptide characterization. Sponsors developing peptides at or near the 40-amino-acid boundary, or those incorporating non-natural modifications, should assess their compound's classification early in development, as this determination shapes the entire regulatory strategy.

Timeline, Cost, and the Value of Comprehensive Upfront Data

The standard IND review period is 30 calendar days. If FDA does not place the IND on clinical hold within that period, the sponsor may proceed with the proposed clinical investigation. A clinical hold, however, can extend the timeline by months—the sponsor must respond to the agency's concerns, and FDA then has 30 days to review the response.

The cost implications of a clinical hold extend beyond direct response preparation. Delays in first-in-human studies affect clinical site agreements, investigator availability, and program timelines that cascade through subsequent development phases. Regulatory precedent consistently indicates that comprehensive upfront CMC and nonclinical data packages reduce the probability of clinical holds, even where they require additional investment at the IND-enabling stage [5].

Sponsors sometimes attempt to submit minimal CMC data for early-phase studies, reasoning that manufacturing processes will evolve before later-phase submissions. While FDA does accommodate process development during Phase 1, the agency expects sufficient characterization to ensure participant safety from the first dose. The threshold is not commercial-scale validation but rather adequate control and understanding of the material being administered to humans.

The Boundary Between Preclinical Research and IND-Enabling Studies

Not all peptide research requires IND submission. Studies conducted entirely in vitro, in animal models, or using compounds obtained through established research exemptions do not trigger the IND requirement. The obligation to file an IND arises when a sponsor intends to administer an investigational drug to human subjects in the United States for the purpose of developing clinical evidence [2].

IND-enabling studies are those specifically designed to generate the data required for IND submission—GLP toxicology studies, validated analytical methods, process development batches, and stability programs. The transition from exploratory preclinical research to IND-enabling work represents a significant increase in regulatory rigor and resource commitment. Sponsors benefit from engaging with FDA through pre-IND meetings before initiating enabling studies, as these interactions allow the agency to identify expectations specific to the compound's mechanism and proposed indication.

The regulatory framework governing peptide IND applications reflects a considered balance between enabling scientific investigation and protecting research participants. The requirements for CMC characterization, nonclinical safety assessment, and analytical method validation are not bureaucratic formalities—they are the evidentiary basis on which FDA determines that human dosing may proceed. For researchers navigating this process, understanding the rationale behind each requirement is as important as understanding the requirement itself.